Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Lumicitabine in Renal Impairment
NCT03189498Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lumicitabine in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 15, Area Under the Plasma Concentration-time Curve From Time Zero to Last Measurable Concentration at Day 15 and 1 more. Started Jul 2017; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03189498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03189498.